Your trusted source for investing success

Tag: novo nordisk

FenoLogica Biosciences Signs Licensing and Collaboration Agreement With the Pacific Northwest Research Institute

FenoLogica Biosciences Inc., a Seattle-WA-based life sciences company, announces completion of a licensing and collaboration agreement with the Pacific Northwest Research Institute (PNRI). FenoLogica also announces closing of its seed investment round that took place on June 13, 2016.

FenoLogica’s technology combines novel quantitative biology measurement techniques with cloud-based analytical tools

INNATE PHARMA: New preclinical data further supporting the development of IPH4301 presented at the AACR meeting

First-in-class anti-MICA/B therapeutic antibody;
New data demonstrate dual mechanism of action of IPH4301, including tumor antigen targeting and immunomodulation;
IND-enabling studies starting in 2016.

MARSEILLE, France, April 18, 2016 (GLOBE NEWSWIRE) — Innate Pharma SA (the “Company” – Euronext Paris: FR0010331421 – IPH) today presented a new set of preclinical data further validating

Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
Novo Nordisk Files for Regulatory Approval of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes

URL: https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/novo-nordisk-regulatory-approval-once-weekly-semaglutide-fda-type-2-diabetes/